Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Active, not recruiting
AstraZeneca
Phase 3
2005-02-08
The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant
with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive
advanced breast cancer who have failed on a previous endocrine treatment
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
Completed
AstraZeneca
Phase 3
2011-03-01
The purpose of this study is to evaluate the efficacy of a new dose of 500mg Fulvestrant with
the standard dose of 250mg in Chinese postmenopausal women with oestrogen receptor positive
advanced breast cancer who have failed a prior endocrine treatment.
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
Unknown status
AstraZeneca
Phase 2
2004-08-30
This phase II trial is studying fulvestrant to see how well it works in treating patients
with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the
growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the
uptake of estrogen by the tumor cells.
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
Unknown status
National Cancer Institute (NCI)
Phase 2
2004-08-30
This phase II trial is studying fulvestrant to see how well it works in treating patients
with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the
growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the
uptake of estrogen by the tumor cells.
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
Unknown status
Gynecologic Oncology Group
Phase 2
2004-08-30
This phase II trial is studying fulvestrant to see how well it works in treating patients
with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the
growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the
uptake of estrogen by the tumor cells.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
